Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IA Pancreatic Cancer Clear all
Completed Not applicable Interventional
View directory record Official record
Conditions
Stage I Adult Liver Cancer, Stage I Colorectal Cancer, Stage IA Gastric Cancer, Stage IA Pancreatic Cancer, Stage IB Gastric Cancer, Stage IB Pancreatic Cancer, Stage II Adult Liver Cancer, Stage IIA Colorectal Cancer, Stage IIA Gastric Cancer, Stage IIA Pancreatic Cancer, Stage IIB Colorectal Cancer, Stage IIB Gastric Cancer, Stage IIB Pancreatic Cancer, Stage IIC Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Adult Liver Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Adult Liver Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Adult Liver Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer, Stage IVA Colorectal Cancer, Stage IVA Liver Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Liver Cancer, Stage IVB Pancreatic Cancer
Interventions
Computer-Assisted Intervention, Vivofit watch, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study, neoadjuvant therapy, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
Beverly Hills, California • Duarte, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab, Surgery
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
Interventions
Durvalumab, Gemcitabine, Nab-paclitaxel, Oleclumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Malignant Digestive System Neoplasm, Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8
Interventions
Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Biological
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases)
Interventions
DSB2455
Drug
Lead sponsor
Duke Street Bio Ltd
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Recurrent Pancreatic Carcinoma
Interventions
Gemcitabine, Sorafenib, Vorinostat, 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, RosetteSep, DEPfff
Drug · Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2022 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, Zoledronic Acid
Drug · Other · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Interventions
RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
Drug
Lead sponsor
RasCal Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
BI 765883, gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
gemcitabine hydrochloride, docetaxel, capecitabine, intensity-modulated radiation therapy, oxaliplatin, pancreatic surgical procedure, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method
Drug · Other · Genetic
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Alhambra, California • Fullerton, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced May 21, 2026, 6:19 PM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
Laboratory Biomarker Analysis, Cytology Specimen Collection Procedure
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced May 21, 2026, 6:19 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Obesity, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Dietary Intervention, Educational Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Dietary Supplement · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
cetuximab, gemcitabine hydrochloride, capecitabine, radiation therapy, bevacizumab, laboratory biomarker analysis
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced May 21, 2026, 6:19 PM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Interventions
SON-DP
Drug
Lead sponsor
Qurgen Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Poorly Differentiated Malignant Neoplasm, Resectable Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Undifferentiated Pancreatic Carcinoma
Interventions
Irinotecan Hydrochloride, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced May 21, 2026, 6:19 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8, Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage 0 Gastric Cancer AJCC v8, Pathologic Stage I Esophageal Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage I Gastric Cancer AJCC v8, Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IA Gastric Cancer AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Stage 0 Colorectal Cancer AJCC v8, Stage 0 Pancreatic Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Patient Monitoring System, Questionnaire Administration, Consultation
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Intraductal Papillary Mucinous Neoplasm of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
erlotinib hydrochloride, conventional surgery, immunohistochemistry staining method, protein expression analysis, biopsy, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
stereotactic body radiation therapy, capecitabine, therapeutic conventional surgery, magnetic resonance imaging, laboratory biomarker analysis
Radiation · Drug · Procedure + 1 more
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
Interventions
Pyrvinium Pamoate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
veliparib, capecitabine, oxaliplatin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Nelfinavir Mesylate, Oregovomab, Stereotactic Body Radiation Therapy, Therapeutic Conventional Surgery
Procedure · Drug · Other + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced May 21, 2026, 6:19 PM EDT